Back to Results

Pulmonx Corp (LUNG)

Pulmonx Corporation is a commercial-stage medical technology company focused on minimally invasive treatment options for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its product portfolio includes the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the LungTraX Platform. LungTraX is a cloud-based quantitative CT analysis service that includes tools such as LungTraX Connect, LungTraX Detect, and StratX Lung report, which support physician workflow and help evaluate patients for treatment. The company serves patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and other international markets. Pulmonx was incorporated in 1995 and is headquartered in Redwood City, California. Its common stock is listed on NASDAQ under the symbol LUNG.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-LUNG
$2.81
36.4% Upside
Undervalued
$3.40
65.0% Upside
Bargain
Fair
0.0%
November 4, 2026
2.2x
1.0x
88.473 M
85.835 M
39.7%
87.6%
-6.0
63.7%
Valuation • Fair Value

Pulmonx Corp (NASDAQ-LUNG) Fair Value by Valuation Model

Review the available estimates for Pulmonx Corp (NASDAQ-LUNG), including Comps Fair Value.

Primary Valuation Read

Fair Value

$2.81

Estimated upside of 36.4% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

Comps Fair Value

$2.81

Comparable-company valuation reference.

Analyst Price Target

$3.40

Analysts imply upside of 65.0%.

How to read these valuation models

Use the 4 available valuation references for Pulmonx Corp (NASDAQ-LUNG) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Pulmonx Corp (NASDAQ-LUNG)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

87.442 M

Current operating scale indicator.

Revenue Forecast

90.8 M

Forward revenue estimate.

EBITDA

-45.49 M

Current operating profitability reference.

EBITDA Forecast

-33.032 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Pulmonx Corp (NASDAQ-LUNG) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Pulmonx Corp (NASDAQ-LUNG)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-3.22

No elevated caution signal from this screen.

Altman Z-Score

-6.0

Lower score that deserves closer risk review.

FCF / Net Income

63.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Pulmonx Corp (NASDAQ-LUNG). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Pulmonx Corp (NASDAQ-LUNG)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 4, 2026

Days to Earnings

43

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Pulmonx Corp (NASDAQ-LUNG), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Pulmonx Corp (NASDAQ-LUNG) Stock Forecast & Technical Outlook

Review Pulmonx Corp (NASDAQ-LUNG) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Pulmonx Corp (NASDAQ-LUNG) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Pulmonx Corp (NASDAQ-LUNG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Pulmonx Corp (NASDAQ-LUNG) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Pulmonx Corp (NASDAQ-LUNG) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Pulmonx Corp (NASDAQ-LUNG) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Pulmonx Corp (NASDAQ-LUNG)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Pulmonx Corp (NASDAQ-LUNG) has a Buy consensus, with 3 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 2
Sell 0
FAQ • Fast Investor Answers

Pulmonx Corp (NASDAQ-LUNG) Stock FAQ

Data-supported answers about Pulmonx Corp (NASDAQ-LUNG), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.81
Estimated upside 36.4%
Valuation Rating
Undervalued
Estimated upside of 36.4%
Analyst Target
$3.40
Implied upside 65.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Pulmonx Corp (NASDAQ-LUNG) is $2.81. This implies an estimated upside of 36.4% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 36.4% versus the current market price.

The available analyst price target for Pulmonx Corp (NASDAQ-LUNG) is $3.40. The analyst target implies estimated upside of 65.0%.

The current financial health read for Pulmonx Corp (NASDAQ-LUNG) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Pulmonx Corp (NASDAQ-LUNG) is November 4, 2026.

The latest available data indicates no current dividend yield for Pulmonx Corp (NASDAQ-LUNG).

The current market capitalization listed for Pulmonx Corp is 88.473 M.

The current enterprise value listed for Pulmonx Corp is 85.835 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Pulmonx Corp is NASDAQ-LUNG, and the stock is listed on NASDAQ.

Pulmonx Corp (NASDAQ-LUNG) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Pulmonx Corp is 39.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Pulmonx Corp is 87.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 179.4 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 142 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 116.1 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 65.099 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 51.173 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.847 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 44.185 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 41.084 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 33.785 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 31.756 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.674 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 29.933 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.452 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 20.357 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 17.926 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.107 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.581 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 12.242 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.566 B